



an Open Access Journal by MDPI

Targeted Radionuclide Therapy (TRNT) in Modern Cancer Management

Guest Editors:

Dr. Martina Benešová-Schäfer

Research Group Molecular
Biology of Systemic
Radiotherapy, Research Program
Imaging and Radiooncology,
German Cancer Research Center
(DKFZ), Im Neuenheimer Feld
223, 69120 Heidelberg, Germany

Dr. Gábor Bakos

Research Group Molecular
Biology of Systemic
Radiotherapy, Research Program
Imaging and Radiooncology,
German Cancer Research Center
(DKFZ), Im Neuenheimer Feld
223, D-69120 Heidelberg,
Germany

Deadline for manuscript
submissions:

closed (15 January 2023)

Message from the Guest Editors

The TRNT approach has been proven clinically highly promising given its experience in the treatment of neuroendocrine tumors or disseminated prostate cancer. The crucial aspect of TRNT is the evaluation of new targets, radionuclides and pharmaceuticals. The mechanisms of resistance and radiation-induced adverse effects limiting patients' survival or quality of life must also be addressed.

Areas of interest include, but are not limited to:

Evaluation of novel targets for cancer treatment and theranostics;

Design and evaluation of novel radiopharmaceuticals for treatment and theranostics;

Evaluation of non-standard/exotic radionuclides potentially suitable for TRNT;

Established and experimental TRNT strategies;

Targeted alpha therapies;

Auger-electron radionuclide therapies;

Radiomunotherapies;

Prospective combination therapies involving TRNT;

Biological effects of TRNT;

Challenges of radiobiology in TRNT;



mdpi.com/si/81411

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com